The use of drug resistance algorithms and genotypic inhibitory quotient in prediction of lopinavir-ritonavir treatment response in human immunodeficiency virus type 1 protease inhibitor-experienced patients

Journal of Clinical Virology

Volumn 38, Issue 2, 2007, Pages 131-138

  Maillard, Anne ^a   Chapplain, Jean Marc ^a   Tribut, Olivier ^a   Bentué Ferrer, Danièle ^a   Tattevin, Pierre ^a   Arvieux, Cédric ^a   Michelet, Christian ^a   Ruffault, Annick ^a  

^a PONTCHAILLOU UNIVERSITY HOSPITAL   (France)

Author keywords

Genotypic inhibitory quotient; Genotypic resistance interpretation's algorithms; HIV 1; Lopinavir

Indexed keywords

AMPRENAVIR; EFAVIRENZ; INDINAVIR; LOPINAVIR PLUS RITONAVIR; NELFINAVIR; PROTEINASE INHIBITOR; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; SAQUINAVIR;

ADULT; AGED; ALGORITHM; ARTICLE; CD4 LYMPHOCYTE COUNT; CLINICAL ARTICLE; DRUG MONITORING; FEMALE; GENOTYPE; GENOTYPIC INHIBITORY QUOTIENT; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; MALE; MUTATION; PRIORITY JOURNAL; ROC CURVE; SALVAGE THERAPY; STATISTICAL SIGNIFICANCE; TREATMENT RESPONSE; VIRUS LOAD;

ADULT; AGED; ALGORITHMS; COHORT STUDIES; DRUG RESISTANCE, VIRAL; FEMALE; GENOTYPE; HIV INFECTIONS; HIV PROTEASE INHIBITORS; HIV-1; HUMANS; MALE; MIDDLE AGED; PYRIMIDINONES; RETROSPECTIVE STUDIES; RITONAVIR; SENSITIVITY AND SPECIFICITY; VIRAL LOAD;

EID: 33846117422     PISSN: 13866532     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jcv.2006.11.011     Document Type: Article

References (33)

1. ANRS AC11 Resistance Study Group. HIV-1 genotypic drug resistance interpretation's algorithms, tables of rules 2004; September 2004. http://www.hivfrenchresistance.org.
2. ANRS AC11 Resistance Study Group. HIV PCR and sequencing procedures: HIV-1; March 2005. http://www.hivfrenchresistance.org.
3. Baxter J.D., et al., and the CPCRA 046 Study Team for the Terry Beirn Community Programs for Clinical Research on AIDS (CPCRA). A randomized study of antiretroviral management based on plasma genotypic antiretroviral resistance testing in patients failing therapy. AIDS 14 (2000) F83-F93
4. Boffito M., Arnaudo I., Raiteri R., Bonora S., Sinicco A., Di Garbo A., et al. Clinical use of lopinavir/ritonavir in a salvage therapy setting: pharmacokinetics and pharmacodynamics. AIDS 16 (2002) 2081-2083
5. Breilh D., Pellegrin I., Rouzés A., Berthoin K., Xuereb F., Budzinski H., et al. Virological, intracellular and plasma pharmacological parameters predicting response to lopinavir/ritonavir (KALEPHAR Study). AIDS 18 (2004) 1305-1310
6. Casado J.L., Moreno A., Sabido R., Marti-Belda P., Antela A., Dronda F., et al. Individualizing salvage regimens: the inhibitory quotient (Ctrough/IC50) as predictor of virological response. AIDS 17 (2003) 262-264
7. Conradie F., Sanne I., Venter W., and Eron J. Failure of lopinavir-ritonavir (Kaletra)-containing regimen in an antiretroviral-naïve patient. AIDS 18 (2004) 1084-1085
8. Delfraissy J.F. Pharmacologie des antiretroviraux. Prise en charge des personnes infectées par le VIH. Recommandations du groupe d'experts (2004), Médecine-Sciences, Flammarion, Paris p. 99-115
9. De Luca A., Cingolani A., Di Giambenedetto, Trotta M.P., Baldini F., Rizzo M.G., et al. Variable prediction of antiretroviral treatment outcome by different systems for interpreting genotypic human immunodeficiency virus type 1 drug resistance. J Infect Dis 187 (2003) 1934-1943
10. Durant J., Clevenbergh P., Halfon P., Delgiudice P., Porsin S., Simonet P., et al. Drug-resistance genotyping in HIV-1 therapy: the VIRADAPT randomised controlled trial. Lancet 353 (1999) 2195-2199
11. Ellner P.D., and Neu H. The inhibitory quotient: a method for interpreting minimum inhibitory concentration data. JAMA 246 (1981) 1575-1578
12. Friend J., Parkin N., Liegler T., Martin J.N., and Deeks S.G. Isolated lopinavir resistance after virological rebound in a ritonavir/lopinavir based regimen. AIDS 18 (2004) 1965-1970
13. Guiard-Schmid J.B., Poirier J.M., Meynard J.L., Bonnard P., Gbadoe A.H., Amiel C., et al. High variability of plasma drug concentrations in dual protease inhibitor regimens. Antimicrob Agents Chemother 47 (2003) 986-990
14. Gonzalez de Requena D., Gallego O., Valer L., Jiménez-Nacher I., and Soriano V. Prediction of virological response to lopinavir/ritonavir using the genotypic inhibitory quotient. AIDS Res Hum Retroviruses 20 (2004) 275-278
15. HIV-1 genotypic drug resistance interpretation's algorithms, tables of rules 2004; September, 2004. http://www.hivfrenchresistance.org.
16. Hoefnagel J.G., van der Lee M.J., Koopmans P.P., Schuurman R., Jurriaans S., van Sighem A.I., et al. The genotypic inhibitory quotient and the (cumulative) number of mutations predict the response to lopinavir therapy. AIDS 20 (2006) 1069-1071
17. Hsu A., Granneman G.R., and Bertz R.J. Ritonavir. Clinical pharmacokinetics and interactions with other anti-HIV agents. Clin Pharmacokinet 35 (1998) 275-291
18. Hsu A., Isaacson J., Brun S., Bernstein B., Lam W., Bertz R., et al. Pharmacokinetic-pharmacodynamic analysis of lopinavir-ritonavir in combination with efavirenz and two nucleoside reverse transcriptase inhibitors in extensively pretreated human immunodeficiency virus-infected patients. Antimicrob Agents Chemother 47 (2003) 350-359
19. Isaacson J., Kempf D., Calvez V., Cohen-Codar I., Descamps D., Guillevic E., et al. Proceedings of the 9th Conf. Retrovir. Opport. Infect (2002) (Abstract 559-T)
20. Kempf D.J., Isaacson J.D., King M.S., Brun S.C., Xu Y., Real K., et al. Identification of genotypic changes in human immunodeficiency virus protease that correlate with reduced susceptibility to the protease inhibitor lopinavir among viral isolates from protease inhibitor-experienced patients. J Virol 75 (2001) 7462-7469
21. La Porte C.J.L., Wasmuth J.C., Burger D.M., and Rockstroh J. Proceedings of the 3rd Int Workshop Clin Pharmacol of HIV Therapy (2002) (Abstract 7.14)
22. Mallon P.W.G., Ray J., and Cooper D.A. Effect of therapeutic drug monitoring on outcome in antiretroviral experienced HIV-infected individuals. J Clin Virol 26 (2003) 223-227
23. Marcelin A.G., Lamotte C., Delaugerre C., Ktorza N., Ait Mohand H., Cacace R., et al. Genotypic inhibitory quotient as predictor of virological response to ritonavir-amprenavir in human immunodeficiency virus type 1 protease inhibitor-experienced patients. Antimicrob Agents Chemother 47 (2003) 594-600
24. Marcelin A.G., Cohen-Codar I., King M.S., Colson P., Guillevic E., Descamps D., et al. Virological and pharmacological parameters predicting the response to lopinavir-ritonavir in heavily protease inhibitor-experienced patients. Antimicrob Agents Chemother 49 (2005) 1720-1726
25. Masquelier B., et al., Groupe d' Epidemiologie Clinique du SIDA en Aquitaine. Human immunodeficiency virus type 1 genotypic and pharmacokinetic determinants of the virological response to lopinavir-ritonavir-containing therapy in protease inhibitor-experienced patients. Antimicrob Agents Chemother 46 (2002) 2926-2932
26. Meynard J.L., et al., Narval Trial Group. Phenotypic or genotypic resistance testing for choosing antiretroviral therapy after treatment failure: a randomized trial. AIDS 16 (2002) 727-736
27. Mocroft A., et al., Euro SIDA study group. Decline in the AIDS and death rates in the EuroSIDA study: an observational study. Lancet 362 (2003) 22-29
28. Parkin N.T., Chappey C., and Petropoulos C.J. Improving lopinavir genotype algorithm through phenotype correlations: novel mutation patterns and amprenavir cross-resistance. AIDS 17 (2003) 955-961
29. Ravela J., Betts B.J., Brun-Vezinet F., Vandamme A.M., Descamps D., van Laethem K., et al. HIV-1 protease and reverse transcriptase mutation patterns responsible for discordances between genotypic drug resistance interpretation algorithms. J Acquir Immune Defic Syndr 33 (2003) 8-14
30. Torti C., Uccelli M.C., Quiros-Roldan E., Gargiulo F., Tirelli V., Lapadula G., et al. Prediction of early and confirmed virological response by genotypic inhibitory quotients for lopinavir in patients naive for lopinavir with limited exposure to previous protease inhibitors. J Clin Virol 35 (2006) 414-419
31. Tribut O., Arvieux C., Michelet C., Chapplain J.M., Allain H., and Bentué-Ferrer D. Simultaneous quantitative assay of six HIV protease inhibitors, one metabolite and two non-nucleoside reverse transcriptase inhibitors in human plasma by isocratic reversed-phase liquid chromatography. Ther Drug Monit 24 (2002) 554-562
32. Tural C., et al., and the Havana Study Group. Clinical utility of HIV-1 genotyping and expert advice: the Havana trial. AIDS 16 (2002) 209-218
33. Zazzi M., Romano L., Venturi G., Shafer R.W., Reid C., Dal Bello F., et al. Comparative evaluation of three computerized algorithms for prediction of antiretroviral susceptibility from HIV type 1 genotype. J Antimicrob Chemother 53 (2004) 356-360